Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 12/20 | 0.39 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27684736 | 0.98 | EPHX1 (0.43) | EPHX1ACHEPAOXCA12CA1 | |
| SCHEMBL28056747 | 0.98 | EPHX1 (0.43) | EPHX1ACHEPAOXCA12CA1 | |
| Hydrochloric Acid SCHEMBL27247810 | 0.96 | EPHX1 (0.42) | EPHX1ACHEPAOXCA12CA1 | |
| SCHEMBL2704670 | 0.94 | EPHX1 (0.37) | EPHX1ACHECYP1A2CA12CA1 | |
| SCHEMBL28659907 | 0.88 | PAOX (0.45) | ACHEPAOXCYP1A2CA12CA1 | |
| SCHEMBL2641404 | 0.86 | EPHX1 (0.33) | EPHX1ACHECYP1A2 | |
| SCHEMBL12502048 | 0.86 | HDAC6 (0.42) | ACHEPAOXCYP1A2CA12CA1 | |
| SCHEMBL2703359 | 0.86 | ALDH1A1 (0.33) | EPHX1ACHE | |
| Hydrochloric Acid SCHEMBL27716907 | 0.84 | ALDH1A1 (0.33) | EPHX1ACHE | |
| Methane SCHEMBL27985713 | 0.84 | ALDH1A1 (0.33) | EPHX1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105985944-B | A kind of new method of intracellular site specific covalent labeled RNA | 中国科学院生物物理研究所 | 2019-05-28 | — | — | CN | claimed |
| CN-105985944-A | Novel method of intracellular site-specific covalent RNA labeling | 中国科学院生物物理研究所 | 2016-10-05 | — | — | CN | claimed |
| WO-2024210572-A1 | NOVEL IMIDAZOLE DERIVATIVE AND USE THEREOF | 주식회사 펠레메드 | 2024-10-10 | — | — | WO | disclosed |
| CN-115417870-A | PD-L1 & NAMPT dual-target inhibitor and application | 中国药科大学 | 2022-12-02 | — | — | CN | disclosed |
| CN-106164072-B | Monocyclic lactam organic compounds for the treatment of bacterial infections | 诺华股份有限公司 | 2019-10-01 | — | — | CN | disclosed |
| CN-110114344-A | New pyrimidine compound and preparation method thereof, and contain pharmaceutical composition of the compound as prevention or treating cancer and the active constituent of diseases associated with inflammation | 韩国化学研究院 | 2019-08-09 | — | — | CN | disclosed |
| CN-105985944-B | A kind of new method of intracellular site specific covalent labeled RNA | 中国科学院生物物理研究所 | 2019-05-28 | — | — | CN | disclosed |
| CN-109608443-A | Heterocycleamide as protein modulator | 葛兰素史密斯克莱知识产权发展有限公司 | 2019-04-12 | — | — | CN | disclosed |
| CN-109563081-A | It can be used as the heterocycleamide class of protein modulators | 葛兰素史克知识产权开发有限公司 | 2019-04-02 | — | — | CN | disclosed |
| CN-109071514-A | Heterocyclic amides as protein modulators | 葛兰素史密斯克莱知识产权发展有限公司 | 2018-12-21 | — | — | CN | disclosed |
| CN-109069489-A | Diamino-alkylamino linked arylsulfonamide compounds having selective activity for voltage-gated sodium channels | 默沙东公司 | 2018-12-21 | — | — | CN | disclosed |
| WO-2008109154-A1 | CHEMOKINE RECEPTOR MODULATORS | ALTIRIS THERAPEUTICS, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
| CN-101044121-A | 4-aminopyrimidine-5-one | HOFFMANN LA ROCHE (CH) | 2007-09-26 | — | — | CN | disclosed |
| US-20070208033-A1 | For use as antimetastatic agent or antiviral agent for HIV infection; N-(4-dipropylaminomethylphenyl)-4-{[(1H-imidazol-2-ylmethyl)-(1-methyl-1H-imidazol-2-ylmethyl)-amino]-methyl}-benzamide; chemokine receptor CXCR4 antagonists | KUREHA CORPORATION (JP) | 2007-09-06 | — | — | US | disclosed |
| CN-1950343-A | Amine-based basic compound and use thereof | KUREHA CORP (JP) | 2007-04-18 | — | — | CN | disclosed |
| US-7176227-B2 | For example, N-(4-{[bis(1H-imidazol-2-ylmethyl)-amino]-methyl}-benzyl)-N',N'-dipropylbutane-1,4-diamine; efficacious against diseases such as infection with HIV virus, rheumatism, and cancer metastasis | KUREHA CORPORATION (JP) | 2007-02-13 | — | — | US | disclosed |
| CN-1694871-A | Imidazolopyridines and methods of making and using the same | BIOGEN INC (US) | 2005-11-09 | — | — | CN | disclosed |
| US-20050165063-A1 | Amine compounds and use thereof | KUREHA CHEMICAL INDUSTRY COMPANY, LIMITED. (JP) | 2005-07-28 | — | — | US | disclosed |
| EP-1550657-A1 | AMINE COMPOUNDS AND USE THEREOF | Kureha Chemical Industry Co., Ltd. (JP) | 2005-07-06 | — | — | EP | disclosed |
| CN-1596255-A | Heterocyclic compounds with potent chemokine receptor binding | ANORMED INC (CA) | 2005-03-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165063-A1 | Amine compounds and use thereof | NR0B2, NR5A2, NR1H4 | EPHX1 1699/4885ACHE 4149/4885PAOX 1676/4885 |
| US-20070208033-A1 | For use as antimetastatic agent or antiviral agent for HIV infection; N-(4-dipropylaminomethylphenyl)-4-{[(1H-imidazol-2-ylmethyl)-(1-methyl-1H-imidazol-2-ylmethyl)-amino]-methyl}-benzamide; chemokine receptor CXCR4 antagonists | CXCR4, CXCR6, CCR5 | EPHX1 2398/4885ACHE 4805/4885PAOX 2774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.